SCHEMBL7622341

SCHEMBL7622341

CC(C)C[C@H](NC(=O)[C@@H](N)Cc1c[nH]c2ccccc12)C(=O)O

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ECE1 P42892 8/20 0.70
ERAP2 Q6P179 4/20 0.66
ACE P12821 2/20 0.65
KDM4E B2RXH2 1/20 0.64
MEN1 O00255 1/20 0.64
LMNA P02545 1/20 0.64
MPO P05164 1/20 0.64
MAPT P10636 1/20 0.64
TSHR P16473 1/20 0.64
BLM P54132 1/20 0.64
PMP22 Q01453 1/20 0.64
KMT2A Q03164 1/20 0.64
HIF1A Q16665 1/20 0.64
ERAP1 Q9NZ08 3/20 0.60
IL1RN P18510 2/20 0.60
MMP2 P08253 2/20 0.59
MMP9 P14780 1/20 0.59
MMP8 P22894 1/20 0.59
MMP1 P03956 1/20 0.59
TP53 P04637 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29794195 1.00 ECE1 (0.70) ECE1ERAP2ACEKDM4EMEN1
SCHEMBL7622335 1.00 ECE1 (0.70) ECE1ERAP2ACEKDM4EMEN1
SCHEMBL29352768 1.00 ECE1 (0.70) ECE1ERAP2ACEKDM4EMEN1
SCHEMBL8776396 1.00 ECE1 (0.70) ECE1ERAP2ACEKDM4EMEN1
SCHEMBL30991071 1.00 ECE1 (0.70) ECE1ERAP2ACEKDM4EMEN1
SCHEMBL29538468 0.98 ERAP2 (0.69) ECE1ERAP2ACEKDM4EMEN1
SCHEMBL30051905 0.97 ECE1 (0.69) ECE1ERAP2ACEKDM4EMEN1
SCHEMBL30051545 0.96 ECE1 (0.65) ECE1ERAP2ACEKDM4EMEN1
SCHEMBL29987530 0.95 ECE1 (0.64) ECE1ERAP2ACEKDM4EMEN1
SCHEMBL30051546 0.95 ERAP2 (0.73) ECE1ERAP2ACEERAP1IL1RN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 155 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122060768-A African swine fever oral vaccine saccharomyces cerevisiae engineering bacteria, and construction method and application thereof 天津科技大学 2026-05-19 CN claimed
US-20260060913-A1 BIOACTIVE WALNUT PEPTIDES FOR TREATING HAIR LOSS L'OREAL (FR) 2026-03-05 US claimed
EP-4695413-A1 PHOSPHONOALANINE OLIGOPEPTIDES AND METHODS OF MAKING AND USE THEREOF Ohio State Innovation Foundation (US) 2026-02-18 EP claimed
US-20250115654-A1 PHARMACEUTICAL COMPOSITION OF GLP-1 RECEPTOR AND GIP RECEPTOR DUAL AGONIST, AND USE THEREOF Fujian Shengdi Pharmaceutical Co., Ltd. (CN) 2025-04-10 US claimed
CN-118561957-B Antarctic krill ACE (angiotensin converting enzyme) inhibitory peptide VKGVF, FGGAL, WLDAN and application thereof 中国水产科学研究院黄海水产研究所 2025-03-04 CN claimed
CN-119350437-A Xanthine oxidase inhibitory peptide of tuna of source Yu Qinggan and application thereof 中国海洋大学三亚海洋研究院 2025-01-24 CN claimed
WO-2024235070-A1 PEPTIDE COMPOUND, COMPOSITION AND USE THEREOF 杭州禾泰健宇生物科技有限公司 2024-11-21 WO claimed
WO-2024216031-A1 PHOSPHONOALANINE OLIGOPEPTIDES AND METHODS OF MAKING AND USE THEREOF OHIO STATE INNOVATION FOUNDATION (US) 2024-10-17 WO claimed
CN-118754965-A GLP-1 and GIP receptor dual agonist compounds and uses thereof 北京拓界生物医药科技有限公司 2024-10-11 CN claimed
CN-118561957-A Antarctic krill ACE (angiotensin converting enzyme) inhibitory peptide VKGVF, FGGAL, WLDAN and application thereof 中国水产科学研究院黄海水产研究所 2024-08-30 CN claimed
CN-113912673-B Sesame-derived low-bitter ACE (angiotensin converting enzyme) inhibitory peptide as well as preparation method and application thereof 河南省农业科学院 2024-02-09 CN claimed
EP-4291647-A1 SUBTILISIN VARIANTS AND THEIR USE Fresenius Kabi iPSUM S.r.l. (IT) 2023-12-20 EP claimed
EP-3766545-B1 ACTIVE AGENT FOR USE IN HAIR GROWTH REGULATION CUTANEON SKIN & HAIR INNOVATIONS GMBH (DE) 2023-08-16 EP claimed
US-20230190879-A1 DUAL-AGONIST COMPOUND FOR BOTH GLP-1 AND GIP RECEPTORS AND APPLICATION THEREOF JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) 2023-06-22 US claimed
CN-115397836-A Novel antibacterial peptide and application thereof 安尼根有限公司 2022-11-25 CN claimed
WO-2022171667-A1 SUBTILISIN VARIANTS AND THEIR USE Fresenius Kabi Ipsum S.R.L. (IT) 2022-08-18 WO claimed
US-20220168206-A1 ACTIVE AGENT FOR USE IN HAIR GROWTH REGULATION CUTANEON - SKIN & HAIR INNOVATIONS GMBH (DE) 2022-06-02 US claimed
US-20220168396-A1 MULTI-RECEPTOR AGONIST AND MEDICAL USE THEREOF JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) 2022-06-02 US claimed
EP-0347890-B1 AMINO ACID NUTRIENT COMPOSITIONS Roussel Morishita Co., Ltd. (JP) 1993-03-17 EP claimed
US-5036052-A Containing a dipeptide of tryptophan and alanine or lecine and no stabilizer; discoloration inhibition MORISHITA PHARMACEUTICAL CO., LTD. (JP) 1991-07-30 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230190879-A1 DUAL-AGONIST COMPOUND FOR BOTH GLP-1 AND GIP RECEPTORS AND APPLICATION THEREOF GLP1R, GIPR, GPR119 ECE1 4035/4885ERAP2 683/4885ACE 3908/4885
US-20260060913-A1 BIOACTIVE WALNUT PEPTIDES FOR TREATING HAIR LOSS TYR, CUTA, ARGLU1 ECE1 4095/4885ERAP2 1999/4885ACE 3524/4885
US-20220168396-A1 MULTI-RECEPTOR AGONIST AND MEDICAL USE THEREOF GLP1R, GIPR, GCGR ECE1 3421/4885ERAP2 1421/4885ACE 2658/4885
US-20250115654-A1 PHARMACEUTICAL COMPOSITION OF GLP-1 RECEPTOR AND GIP RECEPTOR DUAL AGONIST, AND USE THEREOF GLP1R, GIPR, GCGR ECE1 2794/4885ERAP2 1636/4885ACE 4146/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.